| An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. (NCT07033026) | NGM Biopharmaceuticals, Inc | 2025-06-25 |
| A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. (NCT06654726) | NGM Biopharmaceuticals, Inc | 2024-10-21 |
| Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT07511972) | NGM Biopharmaceuticals, Inc | 2023-11-14 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects (NCT04828265) | NGM Biopharmaceuticals, Inc | 2021-04-13 |
| Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function (NCT04823702) | NGM Biopharmaceuticals, Inc | 2021-04-01 |
| A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19 (NCT04582318) | NGM Biopharmaceuticals, Inc | 2020-11-09 |
| A Study of NGM621 in Participants With Geographic Atrophy (NCT04465955) | NGM Biopharmaceuticals, Inc | 2020-07-22 |
| Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) (NCT04210245) | NGM Biopharmaceuticals, Inc | 2020-03-23 |
| Study of NGM395 in Adult Participants (NCT04187339) | NGM Biopharmaceuticals, Inc | 2020-02-13 |
| Study of Aldafermin (NGM282) in Participants With Impaired Renal Function (NCT04179630) | NGM Biopharmaceuticals, Inc | 2019-11-08 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| Study of NGM621 in Participants With Geographic Atrophy (NCT04014777) | NGM Biopharmaceuticals, Inc | 2019-07-26 |
| Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3) (NCT03912532) | NGM Biopharmaceuticals, Inc | 2019-05-16 |
| Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects (NCT03392116) | NGM Biopharmaceuticals, Inc | 2018-01-29 |
| Study of NGM313 in Obese Participants (NCT03298464) | NGM Biopharmaceuticals, Inc | 2017-09-11 |